Global Acute Kidney Injury (AKI) Epidemiology Forecast Report 2021-2030 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Acute Kidney Injury (AKI) – Epidemiology Forecast to 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This ‘Acute Kidney Injury (AKI) – Market Insights, Epidemiology and Market Forecast- 2030’ report delivers an in-depth understanding of the AKI, historical and forecasted epidemiology as well as the AKI market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Acute Kidney Injury Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients, Mortality Adjusted Incident Population of AKI in Hospitalized Patients, Stage-specific Incident Population of AKI, and Age-specific Incident Population of AKI in the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Key Findings
In 2020, the incident population of AKI in the 7MM was 10,907,615. The mortality adjusted incident population of AKI in hospitalized patients in the seven major market, was estimated to be 6,544,569 in 2020.
- The United States encompasses the highest incident population of AKI in hospitalized patients, compared to EU5 and Japan. In the United States, mortality adjusted incident population of AKI in hospitalized patients accounted for 2,231,147 in 2020.
- In 2020, in the United States, there were 1,584,114, 401,606, and 245,426 cases of stage I, stage II, and stage III AKI respectively.
- In the US, the age group of 60-84 accounted for the highest cases in 2020, followed by 85+ years. In contrast, the least cases were found in the age group of 18-59. In 2020, there were 312,361, 1,004,016, and 914,770 cases, for the age groups 18-59 years, 60-84 years, and 85+ years, respectively.
- Epidemiology assessed for AKI showed that Germany accounted for the highest mortality-adjusted incident population of AKI in hospitalized patients in EU5, followed by the UK in 2020. The number of total mortality adjusted incidence of AKI in hospitalized patients is anticipated to be 906,731, 544,235, 506,725, 235,769 and 796,443 in 2020, for Germany, France, Italy, Spain, and UK, respectively.
- Epidemiology assessed for AKI showed that Japan, in 2020, accounted for the second-highest mortality-adjusted incident population of AKI in hospitalized patients in 7MM, about 1,323,519 cases.
Country Wise- Acute Kidney Injury Epidemiology
The epidemiology segment also provides the Acute Kidney Injury epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Scope of the Report
- The report covers the descriptive overview of Acute Kidney Injury, explaining its causes, signs and symptoms, pathophysiology.
- The report provides insight into historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of Acute Kidney Injury.
Report Highlight
- Ten Year Forecast of Acute Kidney Injury
- 7MM Coverage
- The publisher has analysed incident population of Acute Kidney Injury in the 7MM which suggests that the patient pool will increase during the forecast period of 2021-2030.
Key Questions Answered
- What is the disease risk, burden and unmet needs of Acute Kidney Injury?
- What is the historical Acute Kidney Injury patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Acute Kidney Injury in the 7MM?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Acute Kidney Injury?
- Out of the above-mentioned countries, which country would have the highest incident population of Acute Kidney Injury during the forecast period (2021-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?
Key Topics Covered:
1 Key Insights
2 Report Introduction
3 Executive Summary of Acute Kidney Injury (AKI)
4 Disease Background and Overview
4.1 Introduction
4.2 Symptoms
4.3 Types of Acute Kidney Injury (AKI)
4.4 Stages Classification
4.5 Risk Factors
4.6 Etiology
4.7 Pathophysiology
4.8 Biomarkers
4.9 Diagnosis
4.9.1 RIFLE Criteria
4.9.2 AKIN Criteria
4.9.3 KDIGO criteria
4.1 NICE Guidelines on AKI: Prevention, Detection, and Management (2019)
4.10.1 Assessing Risk of AKI
4.10.2 Preventing AKI
4.10.3 Detecting AKI
4.10.4 Identifying the Cause of AKI
4.10.5 Information and Support for Patients and Carers
5 Epidemiology and Patient Population
5.1 Key Findings
5.1 Epidemiology Methodology
5.2 Total Incidence of Acute Kidney Injury (AKI) in Hospitalized Patients in the 7MM
5.3 Total Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the 7MM
5.4 Epidemiology of Acute Kidney Injury (AKI)
5.4.1 United States
5.4.2 Europe
5.4.3 Japan
5.5 The United States
5.6 EU5
5.7 Japan
6 Organizations contributing towards Acute Kidney Injury (AKI)
7 Patient Journey
8 Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9tj1rd
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
